These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
207 related items for PubMed ID: 19219381
1. Effect of GLP-1 treatment on bone turnover in normal, type 2 diabetic, and insulin-resistant states. Nuche-Berenguer B, Moreno P, Esbrit P, Dapía S, Caeiro JR, Cancelas J, Haro-Mora JJ, Villanueva-Peñacarrillo ML. Calcif Tissue Int; 2009 Jun; 84(6):453-61. PubMed ID: 19219381 [Abstract] [Full Text] [Related]
2. Exendin-4 exerts osteogenic actions in insulin-resistant and type 2 diabetic states. Nuche-Berenguer B, Moreno P, Portal-Nuñez S, Dapía S, Esbrit P, Villanueva-Peñacarrillo ML. Regul Pept; 2010 Jan 08; 159(1-3):61-6. PubMed ID: 19586609 [Abstract] [Full Text] [Related]
3. Increased bone resorption in HD patients: is it caused by elevated RANKL synthesis? Avbersek-Luznik I, Balon BP, Rus I, Marc J. Nephrol Dial Transplant; 2005 Mar 08; 20(3):566-70. PubMed ID: 15665031 [Abstract] [Full Text] [Related]
4. Normalizing action of exendin-4 and GLP-1 in the glucose metabolism of extrapancreatic tissues in insulin-resistant and type 2 diabetic states. Moreno P, Nuche-Berenguer B, Gutiérrez-Rojas I, Acitores A, Sancho V, Valverde I, González N, Villanueva-Peñacarrillo ML. J Mol Endocrinol; 2012 Feb 08; 48(1):37-47. PubMed ID: 22065862 [Abstract] [Full Text] [Related]
5. Exendin-4 increases bone mineral density in type 2 diabetic OLETF rats potentially through the down-regulation of SOST/sclerostin in osteocytes. Kim JY, Lee SK, Jo KJ, Song DY, Lim DM, Park KY, Bonewald LF, Kim BJ. Life Sci; 2013 Mar 21; 92(10):533-40. PubMed ID: 23357248 [Abstract] [Full Text] [Related]
6. Regulatory effect of parathyroid hormone on sRANKL-osteoprotegerin in hemodialysis patients with renal bone disease. Doumouchtsis K, Perrea D, Doumouchtsis S, Tziamalis M, Poulakou M, Vlachos I, Kostakis A. Ther Apher Dial; 2009 Feb 21; 13(1):49-55. PubMed ID: 19379170 [Abstract] [Full Text] [Related]
7. Anabolic action of parathyroid hormone is skeletal site specific at the tissue and cellular levels in mice. Iida-Klein A, Zhou H, Lu SS, Levine LR, Ducayen-Knowles M, Dempster DW, Nieves J, Lindsay R. J Bone Miner Res; 2002 May 21; 17(5):808-16. PubMed ID: 12009011 [Abstract] [Full Text] [Related]
8. Amylin exerts osteogenic actions with different efficacy depending on the diabetic status. Gutiérrez-Rojas I, Lozano D, Nuche-Berenguer B, Moreno P, Acitores A, Ramos-Álvarez I, Rovira A, Novials A, Martín-Crespo E, Villanueva-Peñacarrillo ML, Esbrit P. Mol Cell Endocrinol; 2013 Jan 30; 365(2):309-15. PubMed ID: 23178165 [Abstract] [Full Text] [Related]
9. Osteoclastic function is accelerated in male patients with type 2 diabetes mellitus: the preventive role of osteoclastogenesis inhibitory factor/osteoprotegerin (OCIF/OPG) on the decrease of bone mineral density. Suzuki K, Kurose T, Takizawa M, Maruyama M, Ushikawa K, Kikuyama M, Sugimoto C, Seino Y, Nagamatsu S, Ishida H. Diabetes Res Clin Pract; 2005 May 30; 68(2):117-25. PubMed ID: 15860239 [Abstract] [Full Text] [Related]
10. Anabolic Effect of Insulin Therapy on the Bone: Osteoprotegerin and Osteocalcin Up-Regulation in Streptozotocin-Induced Diabetic Rats. Bortolin RH, Freire Neto FP, Arcaro CA, Bezerra JF, da Silva FS, Ururahy MA, Souza KS, Lima VM, Luchessi AD, Lima FP, Lia Fook MV, da Silva BJ, Almeida MD, Abreu BJ, de Rezende LA, de Rezende AA. Basic Clin Pharmacol Toxicol; 2017 Mar 30; 120(3):227-234. PubMed ID: 27651300 [Abstract] [Full Text] [Related]
11. Increased RANK ligand in bone marrow of orchiectomized rats and prevention of their bone loss by the RANK ligand inhibitor osteoprotegerin. Li X, Ominsky MS, Stolina M, Warmington KS, Geng Z, Niu QT, Asuncion FJ, Tan HL, Grisanti M, Dwyer D, Adamu S, Ke HZ, Simonet WS, Kostenuik PJ. Bone; 2009 Oct 30; 45(4):669-76. PubMed ID: 19539794 [Abstract] [Full Text] [Related]
12. Glucagon like peptide 2 has a positive impact on osteoporosis in ovariectomized rats. Xu B, He Y, Lu Y, Ren W, Shen J, Wu K, Xu K, Wu J, Hu Y. Life Sci; 2019 Jun 01; 226():47-56. PubMed ID: 30959027 [Abstract] [Full Text] [Related]
13. Comparison of the effects of genistein and zoledronic acid on the bone loss in OPG-deficient mice. Liu J, Xu K, Wen G, Guo H, Li S, Wu X, Dai R, Sheng Z, Liao E. Bone; 2008 May 01; 42(5):950-9. PubMed ID: 18337202 [Abstract] [Full Text] [Related]
14. Effects of the linagliptin, dipeptidyl peptidase-4 inhibitor, on bone fragility induced by type 2 diabetes mellitus in obese mice. Kanda J, Furukawa M, Izumo N, Shimakura T, Yamamoto N, Takahashi HE, Wakabayashi H. Drug Discov Ther; 2020 Nov 04; 14(5):218-225. PubMed ID: 33116039 [Abstract] [Full Text] [Related]
15. Fish liver oil and propolis as protective natural products against the effect of the anti-epileptic drug valproate on immunological markers of bone formation in rats. Elwakkad AS, El Elshamy KA, Sibaii H. Epilepsy Res; 2008 Jul 04; 80(1):47-56. PubMed ID: 18455911 [Abstract] [Full Text] [Related]
16. The pathophysiology of diabetes involves a defective amplification of the late-phase insulin response to glucose by glucose-dependent insulinotropic polypeptide-regardless of etiology and phenotype. Vilsbøll T, Knop FK, Krarup T, Johansen A, Madsbad S, Larsen S, Hansen T, Pedersen O, Holst JJ. J Clin Endocrinol Metab; 2003 Oct 04; 88(10):4897-903. PubMed ID: 14557471 [Abstract] [Full Text] [Related]
17. Tartrate-resistant acid phosphatase 5b and its correlations with other markers of bone metabolism in kidney transplant recipients and dialyzed patients. Małyszko J, Małyszko JS, Pawlak K, Wołczyński S, Myśliwiec M. Adv Med Sci; 2006 Oct 04; 51():69-72. PubMed ID: 17357281 [Abstract] [Full Text] [Related]
19. Vitamin K2 inhibits glucocorticoid-induced bone loss partly by preventing the reduction of osteoprotegerin (OPG). Sasaki N, Kusano E, Takahashi H, Ando Y, Yano K, Tsuda E, Asano Y. J Bone Miner Metab; 2005 Oct 04; 23(1):41-7. PubMed ID: 15616893 [Abstract] [Full Text] [Related]
20. Circulating levels of tartrate-resistant acid phosphatase in rat models of non-insulin-dependent diabetes mellitus. Suzuki K, Ishida H, Takeshita N, Taguchi Y, Sugimoto C, Nosaka K, Seino Y. J Diabetes Complications; 1998 Oct 04; 12(3):176-80. PubMed ID: 9618074 [Abstract] [Full Text] [Related] Page: [Next] [New Search]